Details of the Drug Combination

General Information of Drug Combination (ID: DC8PG5S)

• Drug Combination Name: PPI-668 + Sofosbuvir
• Indication: Chronic Hepatitis C; Status: Phase 2 [1]
• Component Drugs:
  PPI-668 (DM4EHVB): N.A.
  Sofosbuvir (DMQI86A): Small molecular drug

Molecular Interaction Atlas of This Drug Combination

Indication(s) of PPI-668

Disease Entry	ICD 11	Status	REF
Hepatitis C virus infection	1E51.1	Phase 2	[2]

PPI-668 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Hepatitis C virus Non-structural 5A (HCV NS5A)	TTCJ2X8	POLG_HCV1	Modulator	[4]

Indication(s) of Sofosbuvir

Disease Entry	ICD 11	Status	REF
Hepatitis C	1E51	Approved	[3]

Sofosbuvir Interacts with 2 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[5]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[6]

References

• [1] ClinicalTrials.gov (NCT02371408) A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4
• [2] ClinicalTrials.gov (NCT01859962) Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C. U.S. National Institutes of Health.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [5] Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine. Clin Pharmacol Ther. 2018 Dec;104(6):1191-1198.
• [6] KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913)